CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Metsera currently has no products on the market, but is developing oral and injectable treatments for obesity and diabetes.

Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

Pfizer also has set its sights on becoming a giant in oncology, and to support this, completed the acquisition of Seagen in 2023. Two of Seagen's products in the most recent quarter delivered ...

Metsera rallied to a fresh all-time high on Thursday, as investor optimism was bolstered by a billion-dollar bidding war ...

Elsewhere, the busy earnings season continues with reports due from several notable companies such as Advanced Micro Devices, Palantir (NASDAQ:PLTR), Robinhood, Super Micro Computer, Qualcomm, ARM ...

Coming up: earnings from AMD, Palantir, top pharmaceutical and tech firms; private-sector employment report; consumer sentiment.

She further emphasized, "This is particularly true for Pfizer, which recently experienced failure with its low-molecular-weight oral obesity drug; Novo Nordisk, which lacks its own pipeline and has ...

The article highlights current health news including FDA's action against unapproved fluoride drugs, research linking poor childhood movement skills to rising ACL injuries, potential viral solutions ...

US-China one-year trade truce eases tensions as Fed cuts rates. Nikkei surged above 50,000. Focus shifts to RBA and BoE ...